PMID: 2498959Jan 1, 1989Paper

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice

Psychopharmacology
T G HeffnerD A Downs

Abstract

The adenosine agonists 5'-N-ethylcarboxamideadenosine (NECA), 2-chloroadenosine (2-CLA), N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-(phenylamino)adenosine (CV-1808) and R and S isomers of N6-phenylisopropyladenosine (R-PIA and S-PIA) decreased spontaneous locomotor activity in mice and, except for CPA, did so at doses that did not impair motor coordination, a profile shared by dopamine antagonists. CV-1808, the only agent with higher affinity for A2 as compared with A1 adenosine receptors, displayed the largest separation between locomotor inhibitory and ataxic potency. Like dopamine antagonists, NECA and CV-1808 also decreased hyperactivity caused by d--amphetamine at doses that did not cause ataxia whereas A1-selective adenosine agonists reduced amphetamine's effects only at ataxic doses. Unlike dopamine antagonists, adenosine agonists inhibited apomorphine-induced cage climbing only at doses that caused ataxia. Involvement of central adenosine receptors in these effects was suggested by the significant correlation obtained between potency for locomotor inhibition after IP and ICV administration. Affinity for A1 but not A2 adenosine receptors was significantly correlated with potency for inducing ataxia. T...Continue Reading

References

Jan 1, 1978·Pharmacology, Biochemistry, and Behavior·J R McLeanL L Coughenour
Jun 11, 1979·Life Sciences·C J Niemegeers, P A Janssen
Mar 1, 1977·Pharmacology, Biochemistry, and Behavior·L L CoughenourR B Parker
Jan 1, 1985·Annual Review of Neuroscience·S H Snyder
Mar 1, 1986·Journal of Medicinal Chemistry·M D TaylorT E Mertz
Jun 4, 1987·European Journal of Pharmacology·D W Petcoff, D M Cooper
Nov 16, 1987·Life Sciences·H W HamiltonR F Bruns
Oct 1, 1986·Neuropharmacology·V L Coffin, J M Carney
Jan 1, 1982·Comparative Biochemistry and Physiology. C: Comparative Pharmacology·J W Phillis, P H Wu
Oct 1, 1982·Medical Hypotheses·J W Phillis, P H Wu
Jun 15, 1984·Neuroscience Letters·V L CoffinR A Barraco
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·C LondosJ Wolff
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·R F BrunsS H Snyder
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·S H SnyderJ W Daly
Dec 3, 1981·European Journal of Pharmacology·G G Yarbrough, J C McGuffin-Clineschmidt
Jul 2, 1982·Science·A S Levine, J E Morley
Nov 29, 1982·Life Sciences·D B EvansJ A Bristol
Mar 1, 1957·British Journal of Pharmacology and Chemotherapy·T J HALEY, W G MCCORMICK

❮ Previous
Next ❯

Citations

Apr 15, 1994·Pharmacy World & Science : PWS·M J HigginsT W Stone
Jan 1, 1993·Psychopharmacology·M R ZarrindastM Sabetkasai
Dec 1, 1995·Psychopharmacology·M R ZarrindastM Mohagheghi-Badi
Jan 1, 1993·Molecular Neurobiology·M ZoliK Fuxe
Jul 31, 2009·Psychopharmacology·Ryan K Bachtell, David W Self
May 11, 2005·Experimental Brain Research·Branka JanaćMirjana Stojiljković
May 15, 1991·Biochemical Pharmacology·K A JacobsonM Williams
Aug 28, 1995·Brain Research·M Hillefors-BerglundG von Euler
Mar 24, 1995·European Journal of Pharmacology·M R ZarrindastM Sharifzadeh
Jan 11, 1996·European Journal of Pharmacology·S H Kafka, R Corbett
Aug 1, 1993·Pharmacology, Biochemistry, and Behavior·G E MartinM F Jarvis
May 17, 1996·Psychiatry Research·R WaziriL Christensen
Dec 1, 1993·Brain Research. Molecular Brain Research·D R Weaver
Sep 16, 1991·Neuroscience Letters·S FerréK Fuxe
Dec 1, 1995·General Pharmacology·M SharifzadehM Samini
Dec 1, 1992·Neuroscience·S FerréB B Fredholm
Mar 10, 2004·Pharmacology, Biochemistry, and Behavior·Branka JanaćLjubisa Rakić
Feb 26, 1998·Pharmacology, Biochemistry, and Behavior·A E CorbinT G Heffner
Oct 13, 1998·Pharmacology, Biochemistry, and Behavior·J B BedingfieldF A Holloway
Sep 29, 1999·Progress in Neurobiology·P SvenningssonB B Fredholm
Aug 1, 1997·General Pharmacology·M R Zarrindast, A A Moghadamnia
Feb 7, 1992·Journal of Medicinal Chemistry·K A JacobsonM Williams
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S FerreK Fuxe
Oct 1, 1991·British Journal of Pharmacology·M R Zarrindast, T Nasir
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·J F ChenM A Schwarzschild
Jan 1, 1991·Journal of Neurochemistry·M OrfordD Saggerson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.